Stock DESN DOTTIKON ES HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Dottikon ES Holding AG

Equities

DESN

CH0582581713

Market Closed - Swiss Exchange
Other stock markets
 16:30:41 29/04/2024 BST 		5-day change 1st Jan Change
239.5 CHF +2.79% Intraday chart for Dottikon ES Holding AG +5.04% +4.59%
2023 Dottikon ES Posts Lower Fiscal H1 Net Income; Sales Up MT
2023 Dottikon ES Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • With an expected P/E ratio at 32.54 and 31.28 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DOTTIKON ES HOLDING AG Stock Dottikon ES Holding AG
+4.59% 3.51B
D
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.17% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.77% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.46% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.50% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
A+
AMGEN INC. Stock Amgen Inc.
-4.43% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DESN Stock
  4. Ratings Dottikon ES Holding AG